Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Celgene's Q4 Profit Rises 13% on Strong Revlimid Sales

Biopharmaceutical juggernaut Celgene (NASDAQ: CELG  ) reported its fourth-quarter earnings results before the opening bell today, highlighting double-digit gains in both revenue and EPS growth.

For the quarter, Celgene delivered a 21% increase in revenue to $1.756 billion as product sales increased 22% to $1.725 billion from the year-ago period. Adjusted net income rose 13% to $649 million with adjusted EPS edging higher by 14% to $1.51.

The big story, as always with Celgene, was the growth of anemia drug Revlimid which accounted for roughly 65% of Celgene's total revenue. Sales of its blockbuster drug increased 13% worldwide to $1.14 billion with U.S. and international revenue growth coming in at 15% and 11%, respectively.

Strong gains were also seen from cancer drug Abraxane, which benefited from an expanded approval to treat late-stage pancreatic cancer in 2013 and non-small cell lung cancer in 2012 in the U.S. Abraxane sales rose 90% for the quarter to $202 million with U.S. and international sales up 89% and 92%, respectively.

If there was one disappointing drug to point out, it'd have to be anemia treatment Vidaza, which saw sales slump 22%, primarily because of the introduction of a generic competitor in the U.S., where sales dipped 70% to just $27 million. Overall, Vidaza sales for the quarter came in at $168 million.

Another story worth noting is Celgene's beefed up research and development expenses which, due to increased collaborative pacts, rose 45% to $460 million.

Looking toward fiscal 2014, Celgene reaffirmed its previous guidance calling for revenue of approximately $7.5 billion, representing a 15% year-over-year increase, and EPS to be in the range of $7.00 to $7.20, a gain of roughly 19% over fiscal 2013. 


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2816932, ~/Articles/ArticleHandler.aspx, 3/31/2015 11:39:44 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...